MacroGenics, Inc. (MGNX)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
31.06-0.25 (-0.80%)
At close: 4:00 PM EDT
People also watch:
FPRXXLRNKPTIEPZMXNCR
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open31.07
Prev Close31.31
Bid25.25 x 200
Ask0.00 x
Day's Range30.90 - 31.63
52wk Range14.84 - 36.11
1y Target EstN/A
Market Cap1.08B
P/E Ratio (ttm)-31.44
BetaN/A
Volume110,677
Avg Vol (3m)233,592
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • GlobeNewswire4 days ago

    MacroGenics to Present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable

    Rockville, MD, Sept. 23, 2016-- MacroGenics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of ...

  • GlobeNewswire7 days ago

    MacroGenics Announces the Promotion of Three Executives

    Rockville, MD, Sept. 20, 2016--. MacroGenics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment ...

  • MacroGenics, Inc. – Value Analysis (NASDAQ:MGNX) : September 19, 2016
    Capital Cube8 days ago

    MacroGenics, Inc. – Value Analysis (NASDAQ:MGNX) : September 19, 2016

    Categories: Fundamental Analysis Yahoo Finance Click here to see latest analysis Capitalcube gives MacroGenics, Inc. a score of 38. Our analysis is based on comparing MacroGenics, Inc. with the following peers – Cerulean Pharma, Inc., Gilead Sciences, Inc., Pfizer Inc., Merck & Co., Inc., Xencor, Inc., Stemline Therapeutics, Inc., Bristol-Myers Squibb Company, Amgen Inc. and Eli Lilly and Company (CERU-US, ... Read more (Read more...)